 Lantern Pharma Inc NASDAQ: LTRN announced preclinical data of its drug candidate LP-184, showing its potential to inhibit tumor growth and improve survival in animals models of glioblastoma GBM. LP-184 treatment induced tumor regression evidenced by greater than 106 tumor growth inhibition in two subcutaneous xenograft models of GBM U87 and M1123. 